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With limited data comparing hematopoietic cell transplant out-comes between myeloablative total body irradiation (TBI) con-taining and non-TBI regimens in children with de novo acute
myeloid leukemia, the aim of this study was to compare transplant-out-
comes between these regimens. Cox regression models were used to com-
pare transplant-outcomes after TBI and non-TBI regimens in 624 children
transplanted between 2008 and 2016. Thirty two percent (n=199) received
TBI regimens whereas 68% (n=425) received non-TBI regimens. Five-year
non-relapse mortality was higher with TBI regimens (22% vs. 11%,
P<0.0001) but relapse was lower (23% vs. 37%, P<0.0001) compared to
non-TBI regimens. Consequently, overall (62% vs. 60%, P=1.00) and
leukemia-free survival (55% vs. 52%, P=0.42) did not differ between treat-
ment groups. Grade 2-3 acute graft versus host disease was higher with TBI
regimens (56% vs. 27%, P<0.0001) but not chronic graft versus host dis-
ease. The 3-year incidence of gonadal or growth hormone deficiency was
higher with TBI regimens (24% vs. 8%, P<0.001) but there were no differ-
ences in late pulmonary, cardiac or renal impairment. In the absence of a
survival advantage, the choice of TBI or non-TBI regimen merits careful
consideration with the data favoring non-TBI regimens to limit the burden
of morbidity associated with endocrine dysfunction. 
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ABSTRACT
Introduction 
Hematopoietic cell transplant (HCT) is accepted as the
standard of care for children and adolescents with high risk
or relapsed/refractory acute myeloid leukemia (AML).1-3
Total body irradiation (TBI) or busulfan (Bu) containing
myeloablative conditioning regimens are commonly used
to treat these patients.4,5 In 1992, a randomized trial in
adults showed improved 2-year leukemia-free survival
using conditioning with TBI-cyclophosphamide (Cy) com-
pared to Bu-Cy using oral busulfan formulation, which was
available at that time,6 however, there are limited data in
children and adolescents. Intravenous Bu has subsequently
been developed, which provides more consistent pharma-
cokinetics and reliable dosing.7 Further, pharmacokinetic
targeting of intravenous Bu dosing reduces treatment-relat-
ed toxicity.8 In the modern era, in adults, intravenous Bu-
conditioning has been shown to be associated with
improved non-relapse mortality, and overall and disease-
free survival in comparison to TBI-containing regimens.9,10
However, acute graft versus host disease (GvHD),11 acute
liver injury,12 pulmonary injury (e.g., diffuse alveolar hemor-
rhage), and bloodstream infections1,13,14 are reported to be
higher with TBI-containing compared to non-TBI regimens.
Late complications, including secondary malignancies,
endocrine, metabolic, renal, ocular, and neurocognitive
complications are also higher with TBI-containing com-
pared to non-TBI myeloablative regimens.15-17 Although
TBI-containing regimens are associated with significant
toxicity in children,18 many physicians continue to use TBI-
containing regimens for transplantation for de novo AML in
children and adolescents. In the absence of a randomized
trial comparing TBI-containing versus non-TBI regimens in
children, we utilized data on HCT reported to an observa-
tional registry, the Center for International Blood and
Marrow Transplant Research (CIBMTR) to compare out-
comes between the two treatment groups. 
Methods
Patients
Data were reported prospectively to the CIBMTR, a voluntary
working group of more than 450 transplant centers worldwide
that contribute detailed data on allogeneic and autologous HCT.
Participating centers report consecutive transplants and compli-
ance is monitored by on-site audits. All patients are followed
longitudinally until death or lost to follow-up. Eligible patients
were aged ≤21 years undergoing first allogeneic transplantation
with myeloablative conditioning for de novo AML in first or sec-
ond complete remission between 2008 and 2016 and consented
for research. Excluded were patients with an antecedent hema-
tologic disorder or secondary AML, mismatched related donor
transplant and non-calcineurin inhibitor GvHD prophylaxis reg-
imens. Patients were broadly grouped into TBI-containing (TBI-
Cy), TBI-Cy-fludarabine (Flu) and non-TBI (Bu-Cy and Bu-Flu)
regimens. The study was approved by the Institutional Review
Board of the National Marrow Donor Program.
Endpoint
Grades 2-3 acute GvHD, grade 3-4 acute GvHD, and chronic
GvHD were defined using standard definitions.19,20 Relapse was
defined as the recurrence of AML (morphologic, cytogenetic or
molecular) and non-relapse mortality was defined as death in
remission. Overall survival was defined where death from any
cause was considered an event. Leukemia-free survival was
defined as being alive in continuous remission. Neutrophil recov-
ery was defined as achieving a count of ≥0.5x109/L for 3 consecu-
tive days. Platelet recovery was defined as achieving a count of
≥20x109/L without transfusions for 7 consecutive days. The day-
100 incidence of veno-occlusive disease, systemic bacterial, viral
and fungal infection were compared between the two treatment
groups. The 5-year incidence of post-transplant interstitial pneu-
monitis, congestive heart failure, gonadal dysfunction, growth
hormone deficiency and renal failure severe enough to warrant
dialysis were compared between the two treatment groups.  
Statistical methods 
Patient-related, disease-related, and transplant-related out-
comes were compared between treatment groups using Mann-
Whitney tests (continuous variables) and Fisher’s exact/Chi-
square test (categorical variables). A P-value of <0.05 was consid-
ered statistically significant. Cox regression models were built for
acute and chronic GvHD, non-relapse mortality, relapse, overall
and leukemia-free survival.21 The main effect (TBI-containing vs.
non-TBI regimens) was forced in all models, and other covariates
were retained in the final model if they met a significance level of
less than 0.05. Forward stepwise selection was used to identify
significant covariates. The interaction between the main effect
and significant covariates was examined. Assessment of the pro-
portional-hazards assumption was done by examining the coeffi-
cient of the logarithm of time from transplant to the last follow-
up for each covariate. The coefficients for the covariates which
violated the proportional hazards assumption were added as
time-varying effects. The adjusted survival or cumulative inci-
dence probabilities were calculated based on the final Cox mod-
els.22,23 Center effects were tested for non-relapse mortality,
relapse, overall and leukemia-free survival using the score test.24
All analyses were performed using SAS 9.4 (SAS Institute Inc,
Cary, NC). 
Results
Patient, disease and transplant characteristics 
Six hundred and twenty-four patients transplanted at
124 transplant centers were eligible and their characteris-
tics are shown in Table 1. TBI-containing regimens includ-
ed TBI-Cy (38%, 76 of 199) and TBI-Cy-Flu (62%, 123 of
199). Non-TBI regimens included Bu-Cy (76%, 322 of 425)
and Bu-Flu (24%, 103 of 425). Bu pharmacokinetics with
dose adjustments were performed for 80% (338 of 425) of
non-TBI transplantations. Patient and disease characteris-
tics differed by treatment group. TBI-containing regimens
were less likely to be used for children aged 3 years and
younger, for transplants in first complete remission and
more likely with umbilical cord blood (67%). In very
young children (age ≤3 years, n=170), only 19% (33 of 170)
received a TBI regimen. Bone marrow was the predomi-
nant graft for non-TBI regimen transplants (48%). In vivo T-
cell depletion with anti-thymocyte globulin was common
with non-TBI regimens accounting for 52% of transplanta-
tions compared to only 11% with TBI-containing regi-
mens. The predominant GvHD prophylaxis with TBI-con-
taining regimens was cyclosporine with mycophenolate
and for non-TBI regimen, tacrolimus or cyclosporine with
methotrexate. There were no differences between treat-
ment groups regarding performance score, hematopoietic
co-morbidity index, sites at diagnosis and cytogenetic risk.
Most transplant centers used both TBI-containing and non-
C.E. Dandoy et al.
1840 haematologica | 2021; 106(7)
TBI regimens (n=57) or non-TBI regimens alone (n=53).
Only 14 centers used TBI-containing regimens alone.
Further, between 2012 and 2016, only a third of transplants
used TBI-containing regimens. Non-TBI regimens were
equally likely to be used between 2008 and 2011 and
between 2012 and 2016. The median follow-up of patients
who received TBI-containing regimens was 63 months
(range, 3-122 months) and for those who received non-TBI
regimens, 50 months (range, 3–122 months).
Hematopoietic recovery
The median time to neutrophil recovery was 20 days and
17 days after TBI-containing and non-TBI regimens, respec-
tively (P=0.04). The corresponding time to platelet recovery
were 38 days and 30 days, P=0.002. Consequently, the day-
28 incidence of neutrophil recovery was lower after TBI-
containing (79%, 95% Confidence Interval [CI]: 73–84)
compared to non-TBI regimens (85%, 95% CI: 82–88),
P=0.04. Similarly, day-100 incidence of platelet recovery
was also lower after TBI-containing (81%, 95% CI: 75–86)
compared to non-TBI regimens (87%, 95% CI: 84–90),
P=0.002.  
Acute and chronic graft versus host disease 
Grade 2-3 acute GvHD risk was higher with TBI-contain-
ing compared to non-TBI regimens (Table 2). The day-100
incidence of grade 2-3 acute GvHD were 56% (95% CI: 49–
63) and 27% (95% CI: 22–30), respectively, P<0.0001.
Compared to HLA-matched sibling donors, risks were
higher with HLA-matched unrelated (hazard ratio [HR]
3.03, 95% CI: 1.75–5.25, P<0.0001), HLA-mismatched
unrelated (HR 4.12, 95% CI: 2.18–7.77, P<0.0001), HLA-
matched cord blood (HR 3.02, 95% CI: 1.44 –6.34,
P=0.0035) and HLA-mismatched cord blood (HR 2.95, 95%
CI: 1.57–5.56, P=0.0008). Grade 3-4 acute GvHD risk did
not differ between the treatment groups (Table 2).
Compared to bone marrow grafts, risk of acute GvHD was
higher with peripheral blood (HR 3.22, 95% CI: 1.72–6.03,
P=0.003) and cord blood (HR 2.24, 95% CI: 1.29–3.88,
P=0.0041). Chronic GvHD risk also did not differ between
treatment groups (Table 2). The 5-year incidence of chronic
GvHD was 37% (95% CI: 30– 44) and 30% (95% CI: 26–
35) after TBI-containing and non-TBI regimens. Chronic
GvHD risks were higher in patients aged 11–21 years com-
pared to those aged ≤3 years (HR 1.78, 95% CI: 1,13–2.81,
Table 1. Patient, disease and transplant characteristics.
Variable                                        TBI- regimens        Non-TBI regimens     P-value
Sex                                                                                                                                          0.94
Male/female                                       101 (51%) /                  217 (51%) /                    
                                                                      98 (49%)                      208 (49%)
Age                                                                                                                                       <0.001
≤ 3 years                                                33 (17%)                      137 (32%)                     
4 – 10 years                                           49 (25%)                       93 (22%)                      
11 – 21 years                                        117 (59%)                     195 (46%)                     
Performance score                                                                                                             0.06
90 - 100                                                  168 (84%)                     376 (88%)                     
≤ 80                                                         26 (13%)                       47 (11%)                      
Not reported                                          5 ( 3%)                         2 (<1%)                       
HCT co-morbidity index                                                                                                     0.55
≤ 2                                                          172 (86%)                     375 (88%)                     
≥ 3                                                           25 (13%)                       43 (10%)                      
Not reported                                         2 (  1%)                          7 ( 2%)                        
Site(s) at diagnosis                                                                                                            0.14
Bone marrow only                              132 (66%)                     295 (69%)                     
Bone marrow + central                    52 (26%)                       84 (20%)                      
nervous system
Bone marrow + other sites              12 ( 6%)                        29 ( 7%)                       
Not reported                                          3 ( 2%)                         17 ( 4%)                       
Cytogenetic risk                                                                                                                   0.14
Favorable                                               29 (15%)                        36 ( 8%)                       
Intermediate                                       123 (62%)                     285 (67%)                     
Poor                                                        41 (21%)                       90 (21%)                      
Not reported                                          6 ( 3%)                         14 ( 3%)                       
Disease status at transplant                                                                                            0.006
1st complete remission                     107 (54%)                     277 (65%)                     
2nd complete remission                      92 (46%)                      148 (35%)                     
Donor                                                                                                                                         
HLA-matched sibling                          17 ( 9%)                       123 (29%)                     
HLA-matched unrelated donor        34 (17%)                      109 (26%)                     
HLA-mismatched unrelated             14 ( 7%)                        32 ( 8%)                       
donor
HLA-matched unrelated                    21 (11%)                        29 ( 7%)                       
cord blood
HLA-mismatched unrelated            101 (51%)                      99 (23%)                      
cord blood
Unrelated cord blood                         12 ( 6%)                        33 ( 8%)                       
(not reported)
Graft versus host disease prophylaxis                                                                         <0.001
Tacrolimus + mycophenolate            7 ( 4%)                         42 (10%)                      
Tacrolimus + methotrexate             40 (20%)                      139 (33%)                     
Tacrolimus alone`                                 4 ( 2%)                          8 ( 2%)                        
Cyclosporine + mycophenolate     119 (60%)                      77 (18%)                      
Cyclosporine + methotrexate         20 (10%)                      115 (27%)                     
Cyclosporine alone`                             9 ( 5%)                          44 (10%                       
Anti-thymocyte globulin                         22 (11%)                      221 (52%)               <0.001
Transplant period                                                                                                             <0.001
2008 – 2011                                          133 (67%)                     192 (45%)                     
2012 – 2016                                           66 (33%)                      233 (55%)                     
TBI: total body irradiation; HCT: hematopoietic cell transplant.
Table 2. Results of multivariate analysis
Outcome                                      Events/               Hazard Ratio            P-value
                                                     Number                  (95% CI)                     
Grade 2-4 acute GvHD*                            
TBI-containing regimen                109/196                            1.00
Non-TBI regimen                            112/420                0.44 (0.33 – 0.58)           <0.0001
Grade 3-4 acute GvHD                              
TBI-containing regimen                 34/196                             1.00
Non-TBI regimen                             53/420                 0.69 (0.44 – 1.08)               0.10
Chronic GvHD*                                           
TBI-containing regimen                 70/198                             1.00
Non-TBI regimen                            116/422                0.82 (0.59 – 1.13)               0.23
Non-relapse mortality║                            
TBI-containing regimen                 42/199                             1.00
Non-TBI regimen                             46/425                 0.53 (0.35 – 0.81)              0.003
Relapse#                                                        
TBI-containing regimen                 43/199                             1.00
Non-TBI regimen                            149/425                1.46 (1.04 – 2.07)               0.03
Leukemia-free survival**                          
TBI-containing regimen                 85/199                             1.00
Non-TBI regimen                            195/425                1.01 (0.78 – 1.31)               0.95
Overall survival║                                        
TBI-containing regimen                 73/199                             1.00
Non-TBI regimen                            159/425                0.98 (0.74 – 1.30)               0.91
GvHD: graft versus host disease; TBI. total body irradiation: CI: Confidence Interval; TBI: total
body irradiation; *adjusted for age, donor type and GvHD prophylaxis; ║adjusted for age;
♯adjusted for age and site(s) at diagnosis and **adjusted for age and cytogenetic risk.
TBI versus non-TBI regimens for de novo AML
haematologica | 2021; 106(7) 1841
P=0.01) and 4–10 years (HR 2.29, 95% CI: 1.57–3.33,
P<0.0001). Chronic GvHD was higher with HLA-mis-
matched cord blood compared to HLA-matched sibling
donors (HR 2.04, 95% CI: 1.10–3.67, P=0.02). Chronic
GvHD risks did not differ between other donor groups
(data not shown). 
Non-relapse mortality and relapse
Non-relapse mortality was higher with TBI-containing
regimens (Table 2, Figure 1A). The 1- and 5-year incidence
of non-relapse mortality with TBI-containing regimens
were 17% (95% CI: 12–22) and 22% (95% CI: 16–28). The
corresponding incidence with non-TBI regimens were 8%
(95% CI: 6–11) and 11% (95% CI: 8–15). Compared to
patients aged 4–10 years, non-relapse mortality was higher
in patients aged 11–21 years (HR 1.99, 95% CI: 1.15–3.46,
P=0.01) but not in those aged ≤3 years (HR 1.71, 95% CI:
0.85–3.44, P=0.13). Infections were higher with TBI-con-
taining compared to non-TBI regimens (Table 3A). Veno-
occlusive disease was lower with TBI-containing regimens
(Table 3A). Patients who survived at least 1 year after trans-
plantation in remission were evaluable for organ dysfunc-
tion (Table 3B). Endocrine dysfunction (thyroid or gonadal)
was higher with TBI-containing regimens. Pulmonary, car-
diac and renal complications did not differ between treat-
ment groups.
Relapse risks were lower in TBI-containing regimens
(Table 2, Figure 1B). The 1- and 5-year incidence of relapse
with TBI-containing regimens were 15% (95% CI: 11–22)
and 23% (95% CI: 17– 29). The corresponding relapse inci-
dence with non-TBI regimens were 26% (95% CI: 22–31)
and 37% (95% CI: 32–42), P<0.0001. Relapse risks did not
differ between patients aged 4-10 and 11-21 years (HR 1.17,
95% CI: 0.82–1.69, P=0.39). Relapse was higher in patients
aged ≤3 years compared to those aged 4-10 years (HR 2.49,
95% CI: 1.68–3.69, P<0.0001) and 11–21 years (HR 2.12,
95% CI: 1.51–2.98, P<0.0001). Compared to bone marrow
and central nervous system involvement at diagnosis,
relapse risks were higher in patients with bone marrow
involvement alone (HR 1.93, 95% CI: 1.27–2.93, P=0.002)
and bone marrow with extramedullary site(s) excluding
central nervous system involvement (HR 1.88, 95% CI:
1.01–3.50, P=0.04). Acute grade 2-4 GvHD was associated
with lower relapse risk (HR 0.63, 95% CI: 0.44–0.89,
P=0.008) but this was independent of conditioning regi-
men. The effect of acute grade 3-4 (HR 0.65, 95% CI: 0.39–
1.09, P=0.10) and chronic GvHD (HR 0.74, 95% CI: 0.48–
1.15, P=0.19) on relapse did not meet the level of signifi-
cance that was set a priori.
Overall and leukemia-free survival
There were no differences in overall or leukemia-free sur-
vival by treatment groups (Table 2, Figure 2A and B). Age
was associated with both overall and leukemia-free survival
and cytogenetic risk with leukemia-free survival.
Compared to patients aged 4-10 years, survival was lower
for those aged 11– 21 years (HR 1.82, 95% CI: 1.28–2.59,
P<0.0001) and ≤3 years (HR 2.79, 95% CI: 1.90–4.10,
P<0.0001). Survival was also lower in patients aged ≤3 years
compared to those aged 11–21 years (HR 1.52, 95% CI:
1.14–2.08, P=0.005). Compared to favorable cytogenetics,
leukemia-free survival was lower with intermediate risk
(HR 1.85, 95% CI: 1.10–3.09, P=0.0198) and poor risk (HR
2.46, 95% CI: 1.42–4.27, P=0.0013). The 5-year overall sur-
vival was 61% (95% CI: 54–68) and 61% (95% CI: 56–66)
after TBI-containing and non-TBI containing regimens. The
corresponding leukemia-free survival was 53% (95% CI:
46–60) and 53% (95% CI: 48–58).
Transplant period
As the current analysis included patients transplanted
between 2008 and 2016, we tested for an effect of trans-
plant period (2012-2016 vs. 2008-2011) on non-relapse mor-
tality (HR 0.75, 95% CI 0.48 - 21.17, P=0.21), relapse (HR
1.04, 95% CI: 0.78–1.41, P=0.78), overall (HR 0.93, 95% CI:
0.71– 1.22, P=0.62) and leukemia-free survival (HR 0.96,
C.E. Dandoy et al.
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Figure 1. Non-relapse mortality and relapse. (A) Cumulative incidence of non-relapse mortality with total body irradiation (TBI)-containing and non-TBI regimens, (B)
cumulative incidence of relapse with TBI-containing and non-TBI regimens. 
A B
95% CI: 0.75–1.23, P=0.15) and found none. We also exam-
ined for differences in infection rates by transplant period
and observed lower rate of fungal infection between 2012
and 2016 compared to the earlier period in patients who
received TBI-containing (2% vs. 8%) and non-TBI (1% vs.
4%) regimens. 
Subset analysis
In a subset analysis limited to patients who received Bu-
Cy and Bu-Flu, we examined for an effect of anti-thymo-
cyte globulin on grade 2-4 acute GvHD (HR 0.68, 95% CI:
0.44–1.03, P=0.07), grade 3-4 acute GvHD (HR 0.93, 95%
CI: 0.51–1.70, P=0.82), chronic GvHD (HR 0.75, 95% CI:
0.50–1.12, P=0.16), non-relapse mortality (HR 1.09, 95%
CI: 0.60–1.99, P=0.78), relapse (HR 1.07, 95% CI: 0.77–1.50,
P=0.68), overall (HR 1.24, 95% CI: 0.90–1.72, P=0.19) and
leukemia-free survival (HR 1.05, 95% CI: 0.78–1.40,
P=0.75) and found none.  
Discussion
To our knowledge this is the largest study to compare
TBI and non-TBI intravenous Bu containing regimens in
children and adolescents with de novo AML. Non-relapse
mortality was higher with TBI regimens, and relapse was
TBI versus non-TBI regimens for de novo AML
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Figure 2. Leukemia-free survival and overall survival. (A) Probability of overall survival with total body irradiation (TBI)-containing and non-TBI regimens, (B) proba-
bility of leukemia-free survival with TBI-containing and non-TBI regimens.
A B
Table 3A. Day-100 incidence of veno-occlusive disease and systemic infection.
                                                                          TBI-containing regimen                                              Non-TBI regimen                                             
Outcome                                              N eval                      Probability (95% CI)                  N eval                Probability (95% CI)                       P-value
VOD                                                                   197                                         8% (4-12)                                  422                                15% (11-18)                                       0.03
Bacterial bloodstream infection                199                                       47% (40-54)                                425                                30% (26-35)                                     <0.001
Viral bloodstream infection                         199                                       43% (36-50)                                425                                30% (26-34)                                      0.001
Fungal bloodstream infection                     199                                          6% (3-9)                                   425                                   2% (1-4)                                          0.04
TBI: total body irradiation; VOD: veno-occlusive disease; CI: Confidence Interval; eval: evaluated.
Table 3B. 3-year incidence of organ dysfunction in patients who were alive and in remission for at least 1-year post-transplant
                                                                       TBI-containing regimen                                            Non-TBI regimen                                                  
Outcome                                               N eval                      Probability (95% CI)                  N eval                 Probability (95% CI)                       P-value
Interstitial pneumonitis / Idiopathic          129                                         5% (2-9)                                   267                                  7% (4-11)                                         0.36
pneumonia syndrome 
Endocrine dysfunction (gonadal                125                                      24% (17-32)                                265                                  8% (5-12)                                       <0.001
or growth hormone) 
Cardiac failure, renal failure                        129                                         5% (2-9)                                   267                                   3% (1-5)                                          0.26
requiring dialysis 
Number of events: gonadal dysfunction TBI n=28 of 125; non-TBI n=29 of 265; growth hormone deficiency TBI n=14 of 129, non-TBI n=7 of 265; cardiac failure TBI n=3 of 129,
non-TBI n=1 of 267; renal failure TBI n=4 of 129, non-TBI N=7 of 267. TBI: total body irradiation; CI: Confidence Interval; n: number; eval: evaluated.
higher with non-TBI regimens, negating an advantage for
overall or leukemia-free survival. The net contribution of
non-relapse mortality or relapse for either treatment
group was not sufficient to lead towards an overall or
leukemia-free survival advantage. Our findings are in
keeping with another pediatric study from Japan that also
failed to show differences in overall and leukemia-free
survival between TBI-containing and non-TBI Bu regi-
mens.1 We hypothesize there are several factors that
influenced relapse risks including acute grade 2-4 GvHD.
TBI regimens were largely used with cord blood trans-
plants and TBI-Cy-Flu was the predominant regimen.
Others have reported lower relapse with TBI-Cy-Flu reg-
imen compared to other TBI- and non-TBI containing reg-
imens for cord blood transplant.25 The higher incidence of
bacterial, viral and fungal infections with the TBI-contain-
ing regimens within the first 3 months after transplanta-
tion likely contributed to early transplant-related mortal-
ity. Whether this is an effect of the conditioning regimen
or the type of donor is challenging to differentiate as TBI
regimens were predominantly used for cord blood trans-
plants. In the subset, limited to transplants between 2012
and 2016, the incidence of bacterial and viral infections
was also higher with TBI-regimens and consistent with
the main analysis. However, the incidence of invasive
fungal infection decreased to 2% with TBI regimens and
1% with non-TBI regimens for transplants between 2012
and 2016 (P=0.89) although this had negligible effect on
non-relapse mortality (HR 1.18, P=0.72). A higher 5-year
overall survival recorded with TBI-Cy-Flu compared to
non-TBI regimens may be acceptable for some consider-
ing cord blood transplant even though growth hormone
and gonadal deficiency is higher with TBI-Cy-Flu regi-
men.25 For transplantations with HLA-matched sibling or
adult unrelated donors intravenous Bu-Cy or Bu-Flu is
preferred.26,27 A recent study from the European Society
for Blood and Marrow Transplant (EBMT) observed
lower relapse and higher leukemia-free survival for AML
in first complete remission with Bu-Cy-melphalan com-
pared to Bu-Cy and TBI-Cy.28 Our study did not include
the Bu-Cy-melphalan regimen.
Hematopoietic recovery was lower with TBI-containing
regimens. We hypothesize the lower recovery rates are in
part explained by the predominant use of umbilical cord
blood graft with TBI-containing regimens and in part, by use
of intravenous Bu for all patients and pharmacokinetic data
available for 80% of patients in the non-TBI group. Higher
neutrophil but not platelet recovery with intravenous Bu
containing regimens compared to TBI-containing regimens
has been reported in adults with acute leukemia.10
Consistent with other reports, TBI-containing regimens
were associated with higher incidence of thyroid and
growth hormone deficiency compared to non-TBI regi-
mens.21,22 Although not studied in the current analysis, oth-
ers have recorded higher risk of cataracts, neuropsycholog-
ical and cognitive abnormalities with TBI-containing regi-
mens.22-24 The 5-year incidence of cardiac failure and renal
failure were modest (<10%) but did not differ between
treatment groups. Although not the focus of the current
study, two recent publications studied the association
between myeloablative conditioning regimens and second
neoplasm. Those reports did not record a higher risk with
TBI-containing compared to non-TBI regimens.27,29
There are limitations to studying the effect of trans-
plant conditioning regimen in a retrospective cohort.
First, we do not know the factors that influenced choice
of conditioning regimen other than in the youngest age
group (≤3 years), approximately 70% of those who
received TBI regimen were in second complete remission.
Although we performed a carefully controlled analyses
there may be unknown or unmeasured factors that may
have influenced the outcomes recorded. Second, over the
course of the study, effective molecular flow cytometric
measures of detectable disease in patients in complete
remission at transplantation may have helped refine prog-
nosis after transplantation30 although it can be argued that
the effect of minimal residual disease (MRD) would be
consistent across both treatment groups. Among 166
patients for whom MRD status was available, 6 of 33
(18%) patients who received TBI and 17 of 133 (13%)
patients who received non-TBI regimens were MRD neg-
ative at transplantation. Third, we know most patients
who received Bu had pharmacokinetic dose adjustments,
but we do not have data on dose adjustments to examine
whether an increase or decrease to the prescribed Bu dose
was associated with outcomes. Our study spanned a 9-
year period, a strength considering our sample size, but
leukemia-free and overall survival may be influenced by
transplant period. A careful analysis failed to find an
effect of transplant period on outcomes other than a
lower incidence of invasive fungal infection with TBI reg-
imens. 
Our findings are relevant regarding a discussion on the
choice of TBI-containing or non-TBI regimen when consid-
ering allogeneic transplantation for children and adolescents
with de novo AML. In the absence of a survival advantage
with either regimen group, the non-TBI regimens, Bu-Cy or
Flu-Bu, are preferred although when considering umbilical
cord blood transplantation TBI-Cy-Flu may be preferred.25
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